Elevance Health (ELV) reported third-quarter 2026 earnings on October 21, delivering results that beat internal expectations across several key financial metrics.
Operating revenue came in at $50.4 billion for the quarter, representing a 0.7% increase driven by higher premium yields and CarelonRx product revenue growth.
Adjusted diluted earnings per share reached $6.99, surpassing the company’s own outlook by a meaningful margin that reflected broad operational strength.
The outperformance was attributed to $0.50 per share in operating gains and favorable benefit expense results that came in better than anticipated heading into the quarter.
The benefit expense ratio improved by 70 basis points to 90.6%, a figure that signals tighter cost management and improving margins across the company’s health benefits business.
Carelon Services, Elevance’s growing services division, posted an operating gain of $292 million, a 33.3% increase reflecting the continued expansion of risk-based clinical solutions.
On the back of these results, Elevance raised its full-year 2026 adjusted EPS guidance to at least $29, while also lifting its operating cash flow outlook to at least $6.5 billion.
Management expressed confidence in the company’s multi-year trajectory, stating they see “a clear path to delivering at least 12% adjusted earnings per share growth in 2027, supported by continued margin improvement in health benefits, ongoing expansion of Carelon, and greater operating efficiency across the enterprise.”
Looking further ahead, leadership indicated that “beyond 2027, we believe the actions we are taking today position us to drive sustainable long-term earnings growth,” signaling a commitment to durable performance well past the near-term guidance window.
Medicaid margins are expected to improve in 2027 as rate alignment moves closer to reflecting underlying costs, a development that has been closely watched by analysts tracking the segment.
Medicare Advantage margins are also projected to continue improving, with the company targeting a long-term range of 3% to 5% for that business line.
Commercial pricing remains disciplined according to management, suggesting Elevance is not sacrificing underwriting standards to chase membership growth in a competitive market.
Individual ACA results are running ahead of expectations, with year-end membership in that segment now expected to reach at least 1.2 million, a notable milestone for the business.
Taken together, the Q3 results and updated guidance paint a picture of a company executing on margin recovery while investing in longer-term growth through its Carelon services platform.
